Filing Overview
Xeris Biopharma Holdings, Inc. filed a Form 8-K on January 18, 2022 under Item 2.02 to report certain preliminary results for the year ended December 31, 2021. The filing furnishes a related press release as Exhibit 99.1, but the press release text and preliminary financial figures are not included in the provided filing content.
Financial Results and Liquidity
The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity, or other financial metrics. It only states that preliminary year-end 2021 results were announced.
Material Changes Versus Prior Period
The filing does not provide sufficient information to assess changes versus the prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
No guidance, outlook, management commentary, risks, contingencies, or unusual items are described in the provided filing text. Any such information may have been contained in Exhibit 99.1, which is referenced but not reproduced.
Key Facts to Verify
- Obtain and review Exhibit 99.1 for the preliminary 2021 financial results.
- Verify reported revenue, operating expenses, net loss, adjusted metrics, cash flow, cash and equivalents, and debt.
- Compare preliminary 2021 results with 2020 results and any previously issued guidance.
- Confirm whether the preliminary figures were subject to audit adjustments or other year-end closing changes.